PGLA, up 60% pre market, what is going on with this stock?
************Found out************
Progen's Phase 2 liver cancer trial exceeds efficacy objective (7.64 ) : Co announces the final stage 1 results of its Phase 2 trial of PI-88 in patients who had previously undergone surgical removal of liver cancer. The 48 week data demonstrated that 160 mg of PI-88 showed an improvement in disease-free rate, the primary endpoint, of 25% and prolonged the time to tumor recurrence (disease-free survival) from 27 to 48 weeks, or by 78%, building on the 30-week results announced in December 2006.